Sangamo Therapeutics (SGMOQ) Change in Cash (2010 - 2025)

Sangamo Therapeutics has reported Change in Cash for 16 years, with the latest figure at -$9.6 million in Q4 2025.

• On a quarterly basis, Change in Cash fell 452.59% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was -$22.5 million, a 583.81% decrease from a year earlier, with the FY2025 full-year figure at -$22.5 million, down 583.81% from the prior year.
• Change in Cash was -$9.6 million for Q4 2025 at Sangamo Therapeutics, down from -$9.3 million in the prior quarter.
• The five-year high for Change in Cash was $46.9 million in Q2 2021, with the low at -$58.6 million in Q1 2022.
• Average Change in Cash over 5 years is -$5.6 million, with a median of -$8.8 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2024: Change in Cash slumped 601.64% in 2022, then surged 225.19% in 2024.
• Over 5 years, Change in Cash stood at $1.9 million in 2021, then soared by 206.26% to $5.9 million in 2022, then plunged by 292.54% to -$11.3 million in 2023, then jumped by 124.02% to $2.7 million in 2024, then plunged by 452.59% to -$9.6 million in 2025.
• The last three Change in Cash figures came in at -$9.6 million (Q4 2025), -$9.3 million (Q3 2025), and $13.2 million (Q2 2025), per Business Quant data.